(1)背景:在骨水泥中添加抗生素是治疗假体周围感染的常见做法。在修订案例中,抗生素的数量和类型通常不足,必须添加额外的抗生素。Theaddition,然而,改变产品本身,外科医生成为骨水泥的“制造商”。PMMAe希望阐明抗生素的混合物是否改变所使用的骨水泥的机械稳定性,以及所添加的抗生素是否仍然起作用并且以足够的量释放。(2)方法:我们比较了两种工业制造的含万古霉素的PMMA水泥;低粘度VancogenX®(TECRES,Sommacampagna,意大利)和高粘度Copal®G+V(HeraeusMedicalGmbH,Wehrheim,德国),用两种载有氨基糖苷类的PMMA水泥,手动添加2.0g万古霉素(HexalCT1631)-高粘度Smartset®GHV和中等粘度的抗生素Simplex和妥布霉素(抗生素Simplex®T)。骨水泥的试样用于确定机械稳定性(弯曲强度和弯曲模块),通过HLPC和改良的Kirby-Bauer测定法测定抗生素的释放。(3)结果:所有测试的骨水泥在最初的小时内显示出初始的高释放。24小时后的重复测试显示VancogenX®和Smartset®GHV在Kirby-Bauer测定中的功效降低。在抗微生物测定中,经过数天的长时间释放显示出功能性抗微生物活性成分在这段时间内的释放。但从第21天开始没有VancogenX®的活动。无法检测到ISO弯曲模块的显着差异,但与弯曲模块相比,与参照组的两种粘固剂相比,ISO弯曲强度显著降低了10-15mPa。Simplex®T仅符合ISO5833;添加万古霉素后,Smartset®GHV没有。(4)结论:总之,对于耐甲氧西林葡萄球菌的治疗,建议在40gPMMA粉末中手动添加2g万古霉素.万古霉素在42天的时间内释放,其浓度高于典型葡萄球菌的MIC。PMMA的机械性能刚刚达到,或者没有实现,ISO机械规范。随着时间的推移,Copal®G+V显示出比VancogenX®更好的洗脱。
(1) Background: The addition of antibiotics to bone cements is a common practice in the treatment of periprosthetic joint infections. In revision cases, the amount and type of antibiotic is often insufficient and additional antibiotics must be added. The addition, however, changes the product itself, and the surgeon becomes the \"manufacturer\" of the bone cement. PMMAe wished to clarify whether the admixture of antibiotics changes the mechanical stability of the bone cements used and if the added antibiotics were still functional and released in sufficient quantities. (2) Methods: We compared two industrially manufactured vancomycin-containing
PMMA cements; the low-viscous VancogenX® (TECRES, Sommacampagna, Italy) and the high-viscous Copal® G+V (Heraeus Medical GmbH, Wehrheim, Germany), with two
PMMA cements loaded with aminoglycosides, to which 2.0 g of vancomycin (Hexal CT1631) were manually added-the high-viscous Smartset® GHV and the medium-viscous Antibiotic Simplex with Tobramycin (antibiotic Simplex® T). Test specimens of the bone cements were used to determine mechanical stability (bending strength and bending module), and the release of the antibiotics was determined by HLPC and modified Kirby-Bauer assays. (3) Results: All tested bone cements showed an initial high release within the first hours. Repeated testing after 24 h showed a reduced efficacy of VancogenX® and Smartset® GHV in Kirby-Bauer assays. Long-time release over days showed a release of functional antimicrobial active ingredients over this period of time in anti-microbial assays, but no activity of VancogenX® from day 21 onward. No significant differences in the ISO bending modules could be detected, but in contrast to the bending module, the ISO bending strength was substantially reduced by 10-15 mPal in comparison to both cements of the reference group. The Simplex®T met just the ISO 5833; the Smartset® GHV did not after adding vancomycin. (4) Conclusions: In conclusion, the manual addition of 2 g of vancomycin to 40 g of
PMMA powder is recommended for the treatment of methicillin-resistant staphylococci. Vancomycin is released over a period of 42 days with concentrations above the MIC for typical staphylococci. The mechanical properties of the
PMMA just met, or did not fulfill, ISO mechanical specification. Copal® G+V showed a better elution than VancogenX® over time.